Tag: FDA BIMO

Fix TMF Errors Fast: Misfiles, Missing Signatures, Late Docs

Posted on digi By digi

Fix TMF Errors Fast: Misfiles, Missing Signatures, Late Docs Rapid TMF Remediation: Fixing Misfiles, Missing Signatures, and Late Documents Before Inspectors Ask Why speed matters: converting TMF defects into inspection-ready evidence within days The three failure patterns that derail inspections Across programs, the fastest way to lose credibility is the same: misfiled artifacts that can’t…

Read More “Fix TMF Errors Fast: Misfiles, Missing Signatures, Late Docs” »

Clinical Trial Operations & Data Integrity, TMF & eTMF

MedDRA/WHODrug & Footnotes: Version Control That’s Traceable

Posted on digi By digi

MedDRA/WHODrug & Footnotes: Version Control That’s Traceable Make MedDRA/WHODrug Version Control Traceable: Footnotes, Change Logs, and Evidence That Survive Review Why dictionary version control is a regulatory deliverable (not just a data-management task) What “traceable” means for coded data When reviewers challenge an adverse event count or a concomitant medication pattern, they are really testing…

Read More “MedDRA/WHODrug & Footnotes: Version Control That’s Traceable” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity

TMF QC & Reconciliation SOP: Roles, Cadence, Checklists

Posted on digi By digi

TMF QC & Reconciliation SOP: Roles, Cadence, Checklists TMF QC and Reconciliation SOP: Defining Roles, Cadence, and Checklists that Pass Real Inspections Purpose and scope: a pragmatic SOP that proves control, not bureaucracy What “good” looks like for TMF QC and reconciliation A credible Trial Master File program is simple to explain and fast to…

Read More “TMF QC & Reconciliation SOP: Roles, Cadence, Checklists” »

Clinical Trial Operations & Data Integrity, TMF & eTMF

TMF Timeliness SLAs & Thresholds: Audit-Ready Evidence

Posted on digi By digi

TMF Timeliness SLAs & Thresholds: Audit-Ready Evidence TMF Timeliness SLAs & Thresholds: How to Produce Audit-Ready Evidence That Survives Live Inspection Why timeliness decides inspection outcomes—and how to make it measurable From “filed eventually” to “filed on time—and provably so” Regulators do not ask whether documents exist; they ask whether the Trial Master File (TMF)…

Read More “TMF Timeliness SLAs & Thresholds: Audit-Ready Evidence” »

Clinical Trial Operations & Data Integrity, TMF & eTMF

Listings QC Checklist: Filters, Columns, Logic — No Last-Minute Fixes

Posted on digi By digi

Listings QC Checklist: Filters, Columns, Logic — No Last-Minute Fixes Listings QC That Doesn’t Break on Submission Day: Filters, Columns, and Logic You Can Defend Why listings QC is a regulatory deliverable, not a formatting chore The purpose of listings (and why reviewers open them first) Clinical data listings are where reviewers go when a…

Read More “Listings QC Checklist: Filters, Columns, Logic — No Last-Minute Fixes” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity

Proven TMF KPIs for FDA/MHRA Inspection Readiness

Posted on digi By digi

Proven TMF KPIs for FDA/MHRA Inspection Readiness Proven TMF KPIs for FDA/MHRA Inspection Readiness: The Metrics, Methods, and Evidence That Survive Real Audits Why measurable TMF performance is the fastest path to inspection readiness Anchor your TMF to a small set of outcome-driven KPIs Inspectors don’t reward volume; they reward control. A Trial Master File…

Read More “Proven TMF KPIs for FDA/MHRA Inspection Readiness” »

Clinical Trial Operations & Data Integrity, TMF & eTMF

Double Programming vs Peer Review: Risk-Based Verification

Posted on digi By digi

Double Programming vs Peer Review: Risk-Based Verification Double Programming vs Peer Review: Choosing Risk-Based Verification that Survives Inspection Outcome-first verification: define the decision, then pick the method What success looks like for verification Verification is successful when a reviewer can select any number in any output, travel to the rule that produced it, and re-generate…

Read More “Double Programming vs Peer Review: Risk-Based Verification” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity

Translational Packages: Nonclinical to First-in-Human—What FDA Expects

Posted on digi By digi

Translational Packages: Nonclinical to First-in-Human—What FDA Expects Translational Packages for First-in-Human: What FDA Expects from Nonclinical Through Dose Justification Outcome-first translational strategy: how to earn confidence for first-in-human Define the decision you want the reviewer to sign Your first regulatory milestone is simple to state and hard to win: agreement that the available nonclinical evidence…

Read More “Translational Packages: Nonclinical to First-in-Human—What FDA Expects” »

US Regulatory Submissions

Digital Health & SaMD in Trials: Do You Need an IDE or IND?

Posted on digi By digi

Digital Health & SaMD in Trials: Do You Need an IDE or IND? Digital Health & SaMD in Clinical Trials: A Practical Guide to Choosing IDE vs IND and Writing an Inspection-Ready Rationale Outcome-first thinking: when does a digital tool trigger IDE vs IND—and why it matters to speed and scrutiny Start with the primary…

Read More “Digital Health & SaMD in Trials: Do You Need an IDE or IND?” »

US Regulatory Submissions

SDTM → ADaM Mapping: Inputs, Outputs, Test Cases (US/UK Reviewers)

Posted on digi By digi

SDTM → ADaM Mapping: Inputs, Outputs, Test Cases (US/UK Reviewers) SDTM to ADaM Mapping That Survives Review: Inputs, Outputs, and Test Cases for US/UK Regulators Why SDTM→ADaM mapping is the fulcrum of inspection-readiness What “defensible mapping” really means Defensible mapping is the ability to pick any number in an analysis output and travel—quickly and repeatably—back…

Read More “SDTM → ADaM Mapping: Inputs, Outputs, Test Cases (US/UK Reviewers)” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity